Cardiff Oncology (CRDF) Current Deferred Revenue (2015 - 2018)
Cardiff Oncology (CRDF) posted Current Deferred Revenue of $486636.0 for Q4 2018, up 3.05% sequentially from $472251.0 in Q3 2018, and up 45.51% YoY from $334424.0 in Q4 2017.
Cardiff Oncology (CRDF) Current Deferred Revenue (2015 - 2018) Analysis & Trends
Cardiff Oncology has reported Current Deferred Revenue for 4 years, with the latest figure at $486636.0 in Q4 2018.
- Quarterly Current Deferred Revenue rose 45.51% year-over-year to $486636.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $486636.0 (up 45.51% YoY) and the FY2018 annual result came in at $486636.0, up 45.51% from the prior year.
- Current Deferred Revenue improved to $486636.0 in Q4 2018 per CRDF's latest filing, from $472251.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $486636.0 in Q4 2018 and troughed at $30614.0 in Q4 2015.
- A 4-year average of $313552.3 and a median of $298213.0 in 2017 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue soared 831.75% in 2016, then advanced 6.62% in 2017.
- Over 4 years, Current Deferred Revenue stood at $30614.0 in 2015, then jumped by 831.75% to $285246.0 in 2016, then increased by 17.24% to $334424.0 in 2017, then jumped by 45.51% to $486636.0 in 2018.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $486636.0, $472251.0, and $349565.0 for Q4 2018, Q3 2018, and Q2 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 486,636.00 |
| Sep 30, 2018 | 472,251.00 |
| Jun 30, 2018 | 349,565.00 |
| Mar 31, 2018 | 341,924.00 |
| Dec 31, 2017 | 334,424.00 |
| Sep 30, 2017 | 298,213.00 |
| Jun 30, 2017 | 285,246.00 |
| Mar 31, 2017 | 285,246.00 |
| Dec 31, 2016 | 285,246.00 |
| Sep 30, 2016 | 279,710.00 |
| Dec 31, 2015 | 30,614.00 |